Most Read Articles
Hannah Wong, 30 Sep 2019

Taisho Pharmaceutical launches Lusefi®, an oral anti-diabetic medication for type 2 diabetes mellitus (T2DM). The medication is expected to lower blood glucose and provide adequate glycaemic control, serving as a new alternative prescription for T2DM. Lusefi, with its active ingredient luseogliflozin hydrate, is available in the form of 2.5 mg and 5 mg tablets.

07 Oct 2019
In pancreatic cancer patients undergoing chemotherapy, the presence of diabetes mellitus is associated with reduced survival and larger tumour, as well as with increased risk of death after treatment, according to a meta-analysis.
01 Apr 2019
Basal-bolus therapy using glargine 300 U/mL and insulin glulisine is superior to twice-daily injections of insulin degludec/aspart for glycaemic control without increasing the risk of hypoglycaemia, a new study suggests.

Product Highlight - Forxiga

29 Mar 2019
Forxiga provides early cardiorenal benefits beyond HbA1c in a broad type 2 diabetes patient population
• Superior HbA1c reduction vs DPP4i1-2
• Well-established safety profile with no imbalance of AEs* vs placebo3-5
• Early cardiorenal benefits beyond HbA1C in a broad T2DM patients population6

*AEs included are amputations, fractures, bladder cancer or Fournier’s gangrene
Disclaimer: Forxiga is not indicated to reduce the risk of CV events, CV death or hospitalisation for heart failure or for the treatment of CKD

References:
1. Bailey CJ, Gross JL, Pieters A, Bastein A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo- controlled trial. Lancet. 2010;375(9733):2223-2233.                 
2. Rosenstock J, Mathieu C, Chen H, et al. Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin. Arch Endocrinol Metab. 2018;62(4):424-430
3. Data on file. Atlas Approval ID: 801,453.011. AstraZeneca Pharmaceuticals Ltd.
4. FORXIGA Malaysia Prescribing Information (Doc ID-002317198, Version 13.0). April 2018
5. Jabbour S, Seufert J, Scheen A, Karup C, Langkilde AM. The incidence of amputation in the dapagliflozin clinical trial program. Endoc Pract. 2017;23(1):46A.
6. Wiviott SD, Raz I, Bonaca MP, et al. Dapaglifozin and cardiovascular outcomes in type-2 diabetes. N Engl J Med. 2018. doi: 10.1056/NEJMoa1812389

Further information is available in section 11b and in mims.com.
Full prescribing information is available upon request.


Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Hannah Wong, 30 Sep 2019

Taisho Pharmaceutical launches Lusefi®, an oral anti-diabetic medication for type 2 diabetes mellitus (T2DM). The medication is expected to lower blood glucose and provide adequate glycaemic control, serving as a new alternative prescription for T2DM. Lusefi, with its active ingredient luseogliflozin hydrate, is available in the form of 2.5 mg and 5 mg tablets.

07 Oct 2019
In pancreatic cancer patients undergoing chemotherapy, the presence of diabetes mellitus is associated with reduced survival and larger tumour, as well as with increased risk of death after treatment, according to a meta-analysis.
01 Apr 2019
Basal-bolus therapy using glargine 300 U/mL and insulin glulisine is superior to twice-daily injections of insulin degludec/aspart for glycaemic control without increasing the risk of hypoglycaemia, a new study suggests.